THE COMPARATIVE EFFICACY AND SAFETY OF ATORVASTATIN VERSUS PRAVASTATIN IN DYSLIPIDEMIC PATIENTS ON PERITONEAL DIALYSIS

Authors : Betül ÖĞÜTMEN, Mehmet KOÇ, Serhan TUĞLULAR, Emel AKOĞLU, Çetin ÖZENER

Pages : 90-96

View : 45 | Download : 5

Publication Date : 2016-12-03

Article Type : Research Paper

Abstract :Objective: The aim of our study was to compare the efficacy and safety of atorvastatin versus pravastatin, in dyslipidémie patients on continuous ambulatory peritoneal dialysis insert ignore into journalissuearticles values(CAPD);. Material and methods: Fifty-five hyperlipidémie CAPD patients were randomized to either atorvastatin insert ignore into journalissuearticles values(n=27); or pravastatin insert ignore into journalissuearticles values(n=28); treatment and prospectively followed for nine months. Hyperlipidemia was defined as TC >200mg/dl insert ignore into journalissuearticles values(5.2 mmol/L); and LDL-C >135 mg/dl insert ignore into journalissuearticles values(3.5 mmol/L);. Both drugs were initiated at a dose of 10 mg/day and the doses were increased if LDL-C was >135 mg/dl at visits done every three months. The blood glucose, serum albumin total cholesterol insert ignore into journalissuearticles values(TC);, high-density lipoprotein cholesterol insert ignore into journalissuearticles values(HDL-C);, very low-density lipoprotein cholesterol insert ignore into journalissuearticles values(VLDL-C);, triglyceride insert ignore into journalissuearticles values(TG);, AST, ALT, GGT, uric acid, CPK, HbA1C were measured in the fasting blood samples taken at baseline, and at 3rd, 6th and 9th months of the treatment. Results: Both agents resulted in a marked reduction in the TC, LDL-C and TG levels; but no change was observed for VLDL-C and HDL- C in either of the treatment arms. The proportional decrease of TC and LDL-C was more marked in the atorvastatin group, compared to pravastatin group. No major side effects were observed with either of the statins in these patient groups. Conclusion: The results of our study demonstrated that although both statins improved the lipid profiles and both are safe for use in dyslipidémie CAPD patients, and higher starting doses insert ignore into journalissuearticles values(20 mg); may be required for pravastatin in patients on CAPD treatment. Key Words: Dyslipidemia, Atorvastatin, Pravastatin, Continuous ambulatory peritoneal dialysis insert ignore into journalissuearticles values(CAPD);
Keywords :

ORIGINAL ARTICLE URL